Market Overview

Teva, Perrigo Reports US Launch of Generic Temozolomide

Related TEVA
Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received Tenative FDA Approval for All Strengths; May Start Generic Versions in December
Market Wrap For April 16: Markets Hold On To Gains On Positive Yellen Comments And Economic Data
Pfizer Loses Bid to Hold Celebrex Exclusivity to '15 (Fox Business)
Related PRGO
#PreMarket Primer: Monday, April 7: World Bank Lowers China's 2014 Growth Forecast
Mylan to Buy Swedish Company? - Analyst Blog
Horizon Inks $660M Reverse Merger With Ireland's Vidara (Fox Business)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Perrigo Company (NYSE: PRGO) today announced the launch of the generic equivalent to Temodar® (temozolomide). Teva will manufacture, market and distribute the product in the U.S. and both companies will equally share in the cost and profitability of the product in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

This product is the generic equivalent to Temodar® (temozolomide), indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. Temodar® had annual sales of approximately $423 million in the United States, according to IMS data as of December 31, 2012. The launch of this product provides a quality alternative, making cancer therapy more cost effective for patients who suffer from this devastating cancer.

Posted-In: News FDA

 

Most Popular

Related Articles (PRGO + TEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free